Extensive lymph node surgery may not be necessary for some patients with melanoma

Share :
Published: 30 May 2015
Views: 2183
Rating:
Save
Prof Claus Garbe - University of Tübingen, Tübingen, Germany.

Prof Garbe presents, at a press conference at ASCO 2015, a randomised study finds that surgical removal of the lymph nodes surrounding a melanoma tumour after a positive lymph node biopsy (melanoma found in node) does not improve survival.

Read the news article and watch the interview for more.

Related Videos

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
2 Jun 2024

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel -  MD Anderson Cancer Center, Houston, USA )
2 Nov 2023

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC

Dr Neil Gross - MD Anderson Cancer Center, Houston, USA
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )
27 Oct 2023

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence

Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA
Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence ( Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA )
3 May 2023

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

The role of multidisciplinary tumour board in managing stage 3 lung cancer

Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland
The role of multidisciplinary tumour board in managing stage 3 lung cancer ( Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland )
1 Feb 2023

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )
26 Jan 2023